TA
RIGL icon

Tamarack Advisers’s Rigel Pharmaceuticals RIGL Stock Holding History

Tamarack Advisers’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-571
Closed -$14K – 55
2021
Q4 		$14K Buy
571
+71
+14% +$2.14K 0.01% 48
2021
Q3 		$100K Buy
+500
New +$19.7K 0.03% 42

Other funds holding RIGL

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Tamarack Advisers's RIGL Position: Q3 2023 in Review

Tamarack Advisers sold out of Rigel Pharmaceuticals (RIGL) in Q3 2023, closing a stake of 125,000 shares — an estimated $1.61M sold.

Tamarack Advisers first reported a position in RIGL in Q2 2018 and held it in 21 quarters. The position peaked at $28.6M in Q1 2021. 106 funds tracked by Wall St. Rank hold RIGL as of Q3 2023.

  • Tamarack Advisers reported no remaining Rigel Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Tamarack Advisers sold 125,000 Rigel Pharmaceuticals shares in Q3 2023, an estimated $1.61M.
  • Tamarack Advisers first reported a position in Rigel Pharmaceuticals in Q2 2018 and held it in 21 quarters.
  • Tamarack Advisers's Rigel Pharmaceuticals position peaked at $28.6M in Q1 2021.
  • 106 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2023.

Based on Tamarack Advisers's 13F filing for Q3 2023, filed 16 Nov 2023.